Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863596 | 0.95 | NAAA (0.48) | CA2CA1NAAAALDH1A1MAPK1 | |
| SCHEMBL28343549 | 0.95 | NAAA (0.53) | CA2CA1NAAAMAPK1NPSR1 | |
| SCHEMBL27259516 | 0.93 | CA2 (0.44) | CA2CA1NAAAALDH1A1MAPK1 | |
| SCHEMBL28077392 | 0.93 | NAAA (0.56) | CA2CA1NAAAMAPK1NPSR1 | |
| SCHEMBL28287643 | 0.93 | NAAA (0.56) | CA2CA1NAAAMAPK1NPSR1 | |
| SCHEMBL6871073 | 0.93 | NAAA (0.52) | CA2CA1NAAAALDH1A1MAPK1 | |
| SCHEMBL6871618 | 0.93 | NAAA (0.52) | CA2CA1NAAAALDH1A1MAPK1 | |
| SCHEMBL6863719 | 0.93 | NAAA (0.52) | CA2CA1NAAAALDH1A1MAPK1 | |
| SCHEMBL6863386 | 0.93 | NAAA (0.52) | CA2CA1NAAAALDH1A1MAPK1 | |
| SCHEMBL6870485 | 0.93 | NAAA (0.52) | CA2CA1NAAAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4172961-A | Production of 1,4-butanediol | DENKA CHEMICAL CORPORATION (US) | 1979-10-30 | — | — | US | claimed |
| US-4032583-A | SOLVENT EXTRACTION, DISTILLATION | PETRO-TEX CHEMICAL CORPORATION (US) | 1977-06-28 | — | — | US | claimed |
| CN-107868058-B | Salt of quinazoline derivative, preparation method and application thereof | 上海医药集团股份有限公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-107868059-B | Salt of quinazoline derivative, preparation method and application thereof | 上海医药集团股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| EP-2782893-B1 | PROCESS FOR PRODUCING 1,4-BUTANEDIOL, GAMMA-BUTYROLACTONE AND TETRAHYDROFURAN BY HYDROGENATING DIALKYL MALEATE IN MIXED LIQUID/VAPOR PHASE | CONSER SPA (IT) | 2017-08-23 | — | — | EP | disclosed |
| US-9040756-B2 | Process for producing 1,4-butanediol by hydrogenating dialkyl maleate in mixed liquid/vapor phase | CONSER SPA (IT) | 2015-05-26 | — | — | US | disclosed |
| US-20140316146-A1 | PROCESS FOR PRODUCING 1,4- BUTANEDIOL BY HYDROGENATING DIALKYL MALEATE IN MIXED LIQUID/VAPOR PHASE | CONSER SPA (IT) | 2014-10-23 | — | — | US | disclosed |
| EP-2782893-A1 | PROCESS FOR PRODUCING 1,4- BUTANEDIOL BY HYDROGENATING DIALKYL MALEATE IN MIXED LIQUID/VAPOR PHASE | Conser S.P.A. (IT) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013076747-A1 | PROCESS FOR PRODUCING 1,4- BUTANEDIOL BY HYDROGENATING DIALKYL MALEATE IN MIXED LIQUID/VAPOR PHASE | CONSER SPA (IT) | 2013-05-30 | — | — | WO | disclosed |
| EP-1165633-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2004-07-14 | — | — | EP | disclosed |
| US-6716939-B2 | COMPRISING TITANIUM, MAGNESIUM, HALOGEN AND AN ELECTRON DONOR COMPOUND SELECTED FROM ESTERS OF SUBSTITUTED SUCCINIC ACIDS | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2004-04-06 | — | — | US | disclosed |
| WO-1988000937-A1 | PROCESS FOR THE CO-PRODUCTION OF BUTANE-1,4-DIOL AND GAMMA-BUTYROLACTONE | DAVY MCKEE (LONDON) LIMITED (GB) | 1988-02-11 | — | — | WO | disclosed |
| EP-0223814-A1 | PROCESS FOR THE PRODUCTION OF $i(GAMMA)-BUTYROLACTONE | DAVY McKEE (LONDON) LIMITED (GB) | 1987-06-03 | — | — | EP | disclosed |
| WO-1986007358-A1 | PROCESS FOR THE PRODUCTION OF GAMMA-BUTYROLACTONE | DAVY MCKEE (LONDON) LIMITED (GB) | 1986-12-18 | — | — | WO | disclosed |
| EP-0204730-A1 | PROCESS FOR THE PRODUCTION OF BUTANE-1,4-DIOL | DAVY McKEE (LONDON) LIMITED (GB) | 1986-12-17 | — | — | EP | disclosed |
| WO-1986003189-A1 | PROCESS FOR THE PRODUCTION OF BUTANE-1,4-DIOL | DAVY MCKEE (LONDON) LIMITED (GB) | 1986-06-05 | — | — | WO | disclosed |
| US-4172961-A | Production of 1,4-butanediol | DENKA CHEMICAL CORPORATION (US) | 1979-10-30 | — | — | US | disclosed |
| US-4172961-A | Production of 1,4-butanediol | DENKA CHEMICAL CORPORATION (US) | 1979-10-30 | — | — | US | disclosed |
| US-4032458-A | FROM MALEIC ACID; ESTERIFICATION-DEHYDRATION, HYDROGENATION AND REDUCTION USING COPPER CHROMITE CATALYST | PETRO-TEX CHEMICAL CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
| US-4032583-A | SOLVENT EXTRACTION, DISTILLATION | PETRO-TEX CHEMICAL CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140316146-A1 | PROCESS FOR PRODUCING 1,4- BUTANEDIOL BY HYDROGENATING DIALKYL MALEATE IN MIXED LIQUID/VAPOR PHASE | SDHA, BCKDK, HPD | CA2 1186/4885CA1 954/4885NAAA 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.